Search
  • Search


    Cardiolipin antibody assay for the diagnosis of syphilis

    HUS-yhtymä

    Cardiolipin antibody assay for the diagnosis of syphilis

    1. Competition notice published

      May 11, 11:29 AMMay 11, 2026 11:29 AM
    2. Supplier selection

      Jun 7, 12:00 AMJune 7, 2026 12:00 AM
    3. Contract signed

      Jun 22, 12:00 AMJune 22, 2026 12:00 AM
    4. Contract start date

      Jun 25, 12:00 AMJune 25, 2026 12:00 AM
    5. Result notice published

      Oct 16, 5:53 AMOctober 16, 2026 5:53 AM

    Brief

    Finland: Tenders/HUS-yhtymä/Cardiolipin antibody assay for the diagnosis of syphilis

    Awarded

    The competition has ended and a winner has been selected.

    Brief

    Laboratorie- og analyseutstyr

    HUS Group has entered into an agreement with XboXLab Oy for the delivery of cardiolipin antibody assay test kits for syphilis diagnosis. The services will be delivered to the Clinical Microbiology unit of the HUS Diagnostic Center in Helsinki. The contract has a duration of 2 years and then effective until further notice, with an estimated maximum total value of 250,000 EUR. The procurement is divided into two parts: a flocculation method suitable for serum and cerebrospinal fluid (VDRL method), for which two suppliers will be selected (primary and backup), and a flocculation method for serum (RPR method), for which one supplier will be selected. The primary focus is on products for serum and cerebrospinal fluid. Approximately 15,000-20,000 tests are performed annually. One bid was received for this contract.

    Result

    Winner
    XboXLab Oy
    Number of bids
    1
    Contract value
    €250,000

    About the bid

      The HUS Group (hereinafter HUS or the Client) requested tenders for cardiolipin antibody assay for the diagnosis of syphilis. The object of the procurement is a test kit based on a flocculation method for the determination of cardiolipin antibodies used in syphilis diagnostics. The test kit will be used for the detection of cardiolipin antibodies in serum and/or cerebrospinal fluid (CSF). The goal of this competitive procurement was to get products that are safe to use and also to have products available when they are needed. The procurement is divided into parts as follows: 1) A flocculation method suitable for serum and cerebrospinal fluid (CSF) (VDRL method) 2) A flocculation method for serum (RPR method) Primarily, the Client will use the products under part 1). For part 1), two suppliers will be selected: a primary supplier and a backup supplier. If both the primary supplier and the backup supplier selected for part 1) are unable to supply the contract products, the Client will use the product selected under part 2). For part 2), one supplier will be selected. The subject matter of the procurement also includes all such supplies, that are related and/or are complementary to the products tendered, such as various package sizes and accessories, which are indicated in "Annex 01 Price and product annex". In addition, during the contract period, products belonging to the product groups that are the subject of the contract, may be acquired in accordance with the estimated value of the contract, also when they are not specified in the product annex (please see Annex 02 Agreement_draft). Contract period is 2 years and after that effective until further notice. Approximately 15,000-20,000 tests are performed per year. This figure is an estimate only, and HUS does not commit to the consumption volumes indicated. The final order quantities may be higher or lower than stated. The analyses are carried out at the Clinical Microbiology unit of the HUS Diagnostic Center in Helsinki. The subject matter and requirements of the procurement are described in detail in the invitation to tender and its annexes.Main features of the procedurePROCUREMENT PROCEDURE This procurement is so called "national procurement". It is estimated to be under the EU threshold value defined in the Act on Public Procurement and Concession Contracts (1397/2016, referred to as the Public Procurement Act). According to 100 § of Public Procurement Act the contracting entity shall outline the procurement procedure that it applies in the call for tenders documents. Procurement procedure is described as follows: PROCESSING OF TENDERS The procedure shall include the following phases: Contracting entity 1. Opens the tenders 2. Verifies the suitability of the tenderer 3. Checks that the tenders conform to the invitation to tender 4. Compares the tenders [Possible trial use] 5. Requests and checks certificates and reports on the suitability of the winning tenderer(s) 6. Makes a procurement decision and communicates it to all the tenderers 7. Concludes an agreement with the selected tenderer(s) In steps 2.-5. a contracting entity may (i) select as the winner of the competitive tendering the tenderer best evaluated on the basis of the comparative criteria; or (ii) move to a negotiated procedure. A negotiated procedure may be used if: (i) the competitive tendering procedure did not result in tenders that match the call for tenders; (ii) no tenders could be accepted due to a too high price or other reason; or (iii) HUS deems it necessary to negotiate the details of the tenders All tenderers who have submitted a tender within the time limit and meet the suitability requirements shall be invited to negotiate. The aim of the negotiations is to update the original call for tenders so that the tenderers selected for the negotiations can submit new tenders on the basis of it. Negotiations are conducted on an equal basis with all invited tenderers for the time specified by the HUS. After the negotiations, HUS will deliver an updated call for tenders to all bidders involved in the negotiations, on the basis of which the tenderers will submit new tenders. New tenders are compared according to the criteria described in the new call for tenders and the winning tenderer is selected on the basis of this comparison. Once the winner of the tendering process has been selected, HUS will make the procurement decision and communicate the decision to all tenderers. LANGUAGE OF THE COMPETITIVE TENDERING PROCEDURE The procurement documents are available in English. If a tenderer needs the documents in another language, the tenderer shall be responsible for translation and liable for the associated costs. Tenders must be prepared in English. PARTIAL TENDERS Partial tenders are accepted. The tenderer may submit a tender for either part 1) only, part 2) only, or both parts. PARALLEL TENDERS Parallel tenders are permitted. If a tenderer submits a parallel tender, the parallel tender must meet all the requirements of the invitation to tenders and have the required appendices. Parallel tenders must always be submitted as separate tenders. No more than one (1) parallel tender may be submitted.

      Contact name
      Kilpailutustiimi (Tendering Team)
      Contact phone
      +358 94711
      Contact email
      kilpailutus.tiimi@hus.fi
      Address
      Uutistie 5, 01770 Vantaa

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

    • Description

      Hinta

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    HUS-yhtymä
    Title
    Cardiolipin antibody assay for the diagnosis of syphilis
    Type
    ResultPrequalification
    Main code
    33000000Medical equipments, pharmaceuticals and personal care products
    Supplemental codes

    No supplemental codes from buyer…

    Supplemental codes added by Cobrief

    33141625Diagnostic kits
    33696200Blood-testing reagents
    33696500Laboratory reagents
    Location
    Helsinki-Uusimaa
    Estimated value
    €250,000.00
    Duration
    48 months

    Active similar competitions

    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      CompetitionOct 7, 2026
      Nov 9, 2026(11 days)
    • HUS-yhtymä

      Helse- og sosial tjenesteyting

      HUS Subcontracting genetic diagnostic tests

      HUS Group needs genetic diagnostic test services to support clinical patient work and individual patient treatment decisions. These services are for various clinics within the HUS Joint Municipal Authority for Specialised Health Care, and also for ISLAB (Eastern Finland Laboratory Centre, Joint Authority Enterprise). The services are procured through a dynamic purchasing system. Suppliers must have a yearly turnover of at least EUR 500,000, a risk category of RL1-RL3, professional experience with similar genetic diagnostic test services for reference customers during the last three years, and the laboratory must have accreditation status secured for at least two years. Additionally, candidates must have experience in supplying at least 5000 genetic studies yearly for university-level or similar hospitals within the EU/EEA area. Award criteria for specific competitions will be based on overall financial affordability, which may include price and/or quality.

      Dynamic purchasing systemMar 24, 2025
      May 9, 2030(100+ days)
    • Varsinais-Suomen hyvinvointialue

      Helse- og sosial tjenesteyting

      Laboratoriotutkimuspalvelut

      Varsinais-Suomen hyvinvointialue tarvitsee laboratoriotutkimuspalveluita, joiden kokonaisarvo on enintään 4,04 miljoonaa euroa. Tarjoukset käsitellään kolmessa vaiheessa: tarjoajien soveltuvuuden arviointi, tarjousten tarjouspyynnön mukaisuuden arviointi ja tarjousten kokonaistaloudellisuuden vertailu. Tarjoukset arvioidaan halvimman hinnan perusteella. Tarjoajien on laadittava tarjoukset suomen kielellä.

      CompetitionOct 22, 2026
      Nov 26, 2026(28 days)
      €4,040,000
    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      Blood pressure monitor for toe/ankle and upper arm measurements

      HUS-yhtymä needs a blood pressure monitor for toe/ankle and upper arm measurements, along with device-specific consumables, to be delivered in 2026. The estimated total value of the procurement is approximately EUR 300,000, which includes one device, optional additional devices (up to two), consumables, and a post-warranty maintenance agreement. The device will be used at the Vascular Surgery Outpatient Clinic (Arterial Laboratory) for approximately 5000 ABI and finger pressure measurements annually. The new device's measurement results must be comparable with the currently used Periflux system 6000 peripheral pressure premium. Tenders will be evaluated based on price (65%) and quality (35%).

      CompetitionSep 29, 2026
      Oct 30, 2026(1 day)
    • HUS-yhtymä

      Laboratorie-kits og reagenser

      Automaattinen nukleiinihappojen eristyslaite

      HUS-yhtymä suunnittelee automaattisen nukleiinihappojen eristyslaitteen hankintaa HUS Diagnostiikkakeskuksen Kliinisen mikrobiologian nukleiinihappoanalytiikkaan, sisältäen laitteen, varalaitteen tai kaksi erillistä eristysmoduulia sekä tarvittavat reagenssit ja tarvikkeet. Hankittavalla laitteella on tarkoitus eristää bakteeri-DNA:ta useista eri näytemateriaaleista, ja eristetyn tuotteen tulee olla validoitu bakteerien 16S-geenin PCR-monistamiseen Sanger-sekvensoinnilla. Toimittajia pyydetään tutustumaan liitteenä oleviin kysymyksiin ja toimittamaan vastaukset sähköpostitse osoitteeseen kilpailutus.diagnostiikka@hus.fi. bioMérieux Suomi OY:llä on todennäköisesti sopimus tällä hetkellä.

      PlanningSep 16, 2026
      Jan 16, 2027(79 days)